Medicare Overpaying For EPO In Dialysis, IG Says; Costs Expected To Rise Through 2004
This article was originally published in The Pink Sheet Daily
Executive Summary
The largest providers' acquisition costs for the top 10 dialysis drugs are between 12% and 68% below the Medicare reimbursement rate, an IG report says. The switch to an ASP-based model may help some providers but hurt others.